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 The importance of learning outside the 
classroom and teaching others 
 
 
As I sat down to read this year's case report submissions 
to our summer supplement I came to the realization that 
my decision to not participate in a summer clinical 
elective was a mistake.  I deprived myself of a valuable 
learning experience.  My fellow students, who seized 
hold of this opportunity, gained precious knowledge that 
cannot be learned by sitting in a classroom.  Reading 
about their experiences made me realize that the famous 
physician Sir William Osler was wise when he stated, 
"Medicine is learned by the bedside and not in the 
classroom.  Let not your conceptions of disease come 
from words heard in the lecture room or read from the 
book.  See, and then reason and compare and control.  
But see first".   
  
I invite you to read our fellow students¶ case reports and 
learn vicariously through their writing as they teach us 
the knowledge they gained this summer at the bedside 
and not in the classroom.  As you read these pages Sarah 
O'Connor will teach us an approach to narrow a 
differential diagnosis of hypotonia in a pediatric 
population.  Jeff Landreville will describe the 
management of diabetic foot syndrome: a condition we 
will all likely encounter during our medical training.  
Lilian Wong will teach us why it is important to be an 
astute clinician, as she describes the presentation of 
Graves¶ disease in an elderly patient.  You will also 
learn about a rare tumour of the GI tract as Mark Xu 
tells the tale of a gastric schwannoma.  The importance 
of multidisciplinary management is evident as Arielle 
Mendel teaches us about the complications of 
scleroderma.  Lauren Sham reminds us that multiple 
sclerosis can also affect children and outlines the 
treatment options available to the pediatric population.  
Lastly, Abdul Naeem brings to our attention a 
complication of topical corticosteroid use that will be 
useful knowledge when we prescribe it for our future 
patients.      
  
The writing of a case report is a time consuming 
process; yet, it is an important method to disseminate 
medical knowledge gained through clinical experiences.  
Our fellow students are to be commended for 
undertaking the challenge and contributing to our 
learning beyond the classroom.  It is also important that 
we recognize the exceptional mentorship role 
undertaken by their supervising clinicians.  These 
clinicians not only undertook the responsibility of 
supervising a junior medical student but also provided a 
valuable learning experience and the opportunity for 
scholarly growth.  They are also to be commended for 
their efforts.  We should all aspire to this standard and 
engage in opportunities to teach others during our future 
medical careers. 
  
I hope that you enjoy this year's summer supplement and 
embrace future opportunities to learn outside the 
classroom and teach others. 
  
Melissa J. MacPherson, PhD 
Junior Associate Editor 
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Grumpy? Recognizing and treating the return 
RI*UDYHV¶GLVHDVH 
Lilian Lee Yan Wong (Meds 2013) 
Faculty Reviewer: Dr. Alice Y.Y. Cheng, MD, FRCPC (Department of Medicine, University of Toronto, Division of 
EndRFULQRORJ\DQG0HWDEROLVP&UHGLW9DOOH\+RVSLWDODQG6W0LFKDHO¶V+RVSLWDO) 
 
 C ASE  
Mrs. RS, a previously healthy 60-year-old lady, was referred to the 
Endocrinology clinic by her family physician for assessment of low 
TSH and elevated free T4.  Over the last 2 months, she had been 
experiencing a sensation of neck tightness, mild dysphagia, hoarse 
voice, dry nose and some blood in her sputum every week.  She also 
complained of frequent epistaxis ranging from blood in mucous to 
frank red blood from her nose with dizziness.  Her appetite was 
LQFUHDVHGDQGVKHEHOLHYHGWKDWKHUERG\³GRHVQ¶WDEVRUEDQ\WKLQJ
ZHOO´6KHKDGQRZHLJKWORVV0UV56GRHVQRWKDYHFROGRUKHDW
intolerance.  Her other complaints included fatigue, feeling anxious 
and irritable, and blurry vision when reading at night-time with the 
occasional white flash.  Her last optometry visit was 7 years ago. 
She admitted to having seasonal allergies that have been improving 
over the last 10 years, for which she took over-the-counter allergy 
medications in the past.  She has also used Nasonex for her nose in 
the past, prescribed by her family doctor.  Her current medications 
include vitamins, Fosamax, calcium, magnesium and glucosamine.  
She denied taking any herbal supplements.  She has no known drug 
allergies.  
Her past medical history is significant for thyroid disease 10 years 
ago.  She was unsure of the type of disease, but recalls taking 
medications for 2 years and stopping when her disease subsided.  She 
also had a history of osteoarthritis (OA) in her hands for 8 years. 
Her family history is significant only for OA in her mother.  She 
denied any family history of thyroid disease.  Mrs. RS has also had 
no surgeries or hospitalizations. 
Her social history revealed that Mrs. RS is originally from the 
Philippines, of Chinese decent, and immigrated to Canada 20 years 
ago.  She lives with her husband, her son, her daughter-in-law and 
her 2 grandsons.  She works part-time in a coffee shop.  She has 
never smoked cigarettes or used recreational drugs, and only has one 
drink at Christmas. 
On examination, Mrs. RS sat comfortably in no apparent distress.  
Her weight was 100 lbs with a height of 5 feet 5 inches.  Heart rate 
was 72 beats/minute and regular with a blood pressure of 110/60 
mmHg and a respiration rate of 16 breaths/minute.  Upon head and 
neck exam, she had full ocular movements with no lid lag, retraction 
or proptosis.  Her thyroid was normal to palpation, with no lumps or 
enlargement.  There was a soft painless lymph node in her right 
posterior cervical chain that measured under 1 cm.  Auscultation of 
her thyroid revealed no bruits.  Nasal conchae look red and dry with 
dried blood.  
Her lab results from her referral showed a TSH <0.05 mIU/L, free T4 
25 pmol/L.  Neutrophils were reduced at 1.7x109/L.  B12 was 
decreased at 160 pmol/L. 
0UV56ZDVGLDJQRVHGZLWKUHFXUUHQW*UDYHV¶GLVHDVHDQGVWDUWHGRQ
methimazole 5 mg daily. Her TSH, free T4 and free T3 will be 
followed regularly.  She was advised to return to her family doctor 
for B12 injections and follow-up for her epistaxis, most likely due to 
allergic rhinitis.  Additionally, she was counseled to consult 
optometry for her vision changes. 
 
DISC USSI O N 
*UDYHV¶GLVHDVHLVLQFUHDVLQJLQSUHYDOHQFHDIIHFWLQJDERXWRI
Canadians, and more common in women than men.1  Thyroid 
stimulating IgG antibodies (TSI) circulate in the body and activate 
the thyrotropin receptor resulting in follicular hyperplasia and 
hypertrophy.2  This enlarges the thyroid and increases thyroid 
hormone (T3 and T4) production.  Excess T3 and T4 work on the 
pituitary, the heart, the liver, bone, reproductive organs, fat and 
muscle resulting in manifestations of thyrotoxicosis, summarized in 
Table 1. 
 
'LDJQRVLVRI*UDYHV¶GLVHDVHFDQEHPDGHFOLQLFDOO\E\HYDOXDWLQJ
patients for hyperthyroidism signs and symptoms.  Symptoms 
include weight loss, heat intolerance, insomnia, tremor, increased 
defecation, proximal muscle weakness, irritability, menstrual 
irregularity and erectile dysfunction with decreased libido and 
possible gynaecomastia in men.2  Signs include tachycardia, 
³*UDYHV¶VWDUH´OLGODJSURSWRVLVJRLWHUUHVWLQJWUHPRU
hyperreflexia, warm and moist skin.2  Rarely, patients can present 
with pretibial myxedema and thyroid-induced clubbing. Usually, 
patients will report increased appetite and food intake with 
paradoxical weight loss.  
 
The case patient, Mrs. RS, did not present to clinic with overt 
hyperthyroidism symptoms and only reported similar anxiety and 
irritability that she experienced during her past thyroid problems.  
Notably, the irritability was ³RXWRIKHUFRQWURO´DQGZDVVWDUWLQJWR
impact her home and work environments.  Otherwise, her history and 
SK\VLFDOZHUHZLWKLQQRUPDOSDUDPHWHUV7KLV³DSDWKHWLF
K\SHUWK\URLGLVP´LVPRUHW\SLFDOLQROGHUSDWLHQWVZKRSUHVHQWZLWK
weight loss or depression.2  Compared to younger patients, they are 
less likely to exhibit tachycardia, tremor, goiter, exophthalmos or 
increased appetite.3  
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Table 1: Thyroid hormone action and resulting manifestations of 
thyrotoxicosis 
System  Action of thyroid 
hormones 
M anifestations of 
thyrotoxicosis 
Pituitary Suppress TSH 
production 
Decreased TSH in labs 
Cardiac Increased channel 
expression, increased Į-
MHC and decreased ȕ-
MHC expression, 
increased serum atrial 
natriuretic peptide 
Increased heart rate and 
contractility 
Hepatic Increased D1 
deiodinase, LDL and 
VLDL receptors, lipase, 
and liver metabolism 
enzymes 
Increased peripheral T3 
production, reduced 
total cholesterol, LDL 
cholesterol and 
lipoprotein(a) 
Skeletal Increased osteocalcin, 
alkaline phosphatase 
Increased bone 
turnover, osteopenia, 
osteoporosis and 
fractures 
Reproductive Male: increased sex 
hormone globulin and 
reduced free 
testosterone 
Female: antagonism of 
estrogen action, 
impaired gonadotropin 
regulation 
Male: erectile 
dysfunction, decreased 
libido 
Female: irregular 
menses 
 
Metabolic Increased fatty acid 
oxidation and sodium-
potassium ATPase 
Increased 
thermogenesis and 
oxygen consumption 
White fat Increased adrenergic 
lipolysis 
Reduced fat mass 
M uscle Increased SERCA 
activity, and serum 
creatinine kinase 
Proximal muscle 
weakness, fatigue 
$GDSWHGIURP%UHQW*$*UDYHV¶'LVHDVH1(QJO-0HG
358(24).  
,QYHVWLJDWLRQVWRFRQILUP*UDYHV¶GLVHDVHLQFOXGHVXSSUHVVHGVHUXP
TSH and elevated T3 and T4 levels.  T3 OHYHOVLQ*UDYHV¶DUHHOHYDWHG
greater than T4 due to action of thyroid hormones on the liver 
producing more D1-iodinases for peripheral conversion of T4 to T3.  
Further testing for TSI antibodies and radioactive-uptake scans may 
be useful in some patients; however, they are not necessary for 
diagnRVLVRUPDQDJHPHQWRI*UDYHV¶GLVHDVH,Q*UDYHV¶SDWLHQWV
TSI antibodies would be present in the blood and the thyroid would 
have elevated uptake of radioactive iodine homogeneously.2  As 
such, with TSH <0.05 and free T4 elevated, the case patient RS has 
*UDYHV¶GLVHDVH 
7UHDWPHQWRI*UDYHV¶GLVHDVHLQFOXGHVWKUHHRSWLRQVDQWLWK\URLG
medications, radioactive iodine ablation and surgical management.4  
Antithyroid medications include the thionamides, propylthiouracil 
(PTU) and methimazole (MMI), which inhibit thyroid peroxidase 
and subsequent thyroid hormone synthesis.4  MMI is more effective 
than PTU and with less adverse reactions even on higher doses.5  
PTU is favoured during pregnancy as MMI is rarely associated with 
teratogenicity: aplasia cutis and gastrointestinal defects.  
Thionamides are generally started until patients are euthyroid, then 
ZLWKGUDZQIRUUHPLVVLRQRI*UDYHV¶GLVHDVH+RZHYHUWKHHVWLPDWHG
UHFXUUHQFHUDWHRI*UDYHV¶RQWKLRQDPLGHVLVHVWLPDWHGWREH-
60%,4 as was in the case of Mrs. RS.  Thionamide-induced 
hypothyroidism correlates to a higher remission rate.6  Radioiodine 
(I-131) ablation is used to induce hypothyroidism to prevent 
UHFXUUHQFHVRI*UDYHV¶GLVHDVHDQGLVHIIHFWLYH/HDVWRIWHQ
surgical thyroidectomy can be used but is reserved for patients with 
complications of antithyroid medication, those who decline 
radioiodine and those with large goiters or thyroid nodules.2  Total 
thyroidectomy has similar complications as subtotal thyroidectomy, 
however ST has a 30% recXUUHQFHUDWHIRU*UDYHV¶7 and thus total 
thyroidectomy is preferred.8  Generally, in non-pregnant patients 
ZLWKRXWKHSDWLFGLVHDVHWKHLQLWLDOWUHDWPHQWIRU*UDYHV¶GLVHDVHLV
MMI. 
5HFXUUHQFHRI*UDYHV¶GLVHDVHLVWUHDWHGVLPLODUWRQDwYH*UDYHV¶
disease.  However, some patients may need definitive treatment with 
radioiodine or thyroidectomy.  These patients are usually 
hypothyroid post-treatment and are treated with L-thyroxine until 
their TSH values are within normal parameters. 
 
C O N C L USI O NS 
*UDYHV¶GLVHase is a common problem presenting to family 
physicians and endocrinology clinics.  Despite the typical textbook 
SUHVHQWDWLRQVRI*UDYHV¶GLVHDVHLQGLYLGXDOSDWLHQWV¶VLJQVDQG
symptoms are varied and one needs to seek context with laboratory 
confirmation to make the diagnosis.  Treatment is also individualized 
to patient needs and can include antithyroid medication, radioiodine 
(RAI) ablation or thyroidectomy.  Recurrence rates are 50-60% with 
antithyroid drugs, 20% in RAI ablation, 30% in subtotal 
thyroidectomy and <1% in total thyroidectomy.  Recurrences are 
treated similarly to naïve disease.  Recognition and treatment of 
UHFXUUHQFHVRI*UDYHV¶GLVHDVHDUHLPSRUWDQWWRUHGXFHFRPSOLFDWLRQV
DQGLQFUHDVHSDWLHQWV¶TXDOLW\RIOLIH 
 
Resources for patients ZLWK*UDYHV¶GLVHDVH1DWLRQDO*UDYHV¶
Disease Foundation (www. Ngdf.org), the American Thyroid 
Association (www.thyroid.org/patients/patients.html) and the 
Thyroid Foundation of Canada (www.thyroid.ca). 
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$QDSSURDFKWRWKH³IORSS\FKLOG´FOLQLFDOO\
narrowing the differential diagnosis of 
hypotonia in the pediatric population 
6DUDK2¶&RQQRU0HGV 
Faculty Reviewer: Dr. R. Garth Smith MB, BS, FRCPC 'HSDUWPHQWRI3HGLDWULFV4XHHQ¶V8QLYHUVLW\ 
 
IN T R O DU C T I O N 
Hypotonia, defined as a reduced tension in a muscle at rest, is a 
relatively frequent presentation in both the infantile and childhood 
period.  It must be differentiated from muscle weakness (a reduction 
in muscle power, that may or may not accompany hypotonia), and 
laxity (an increase in joint range of motion that often accompanies 
hypotonia). 
The possible causes of hypotonia in an infant or child are numerous, 
and include problems with: the brain, the spinal cord, the peripheral 
nerves, the neuromuscular junction, and skeletal muscles.  The 
clinical exam of the hypotonic infant or child will yield many clues 
that the astute physician (or medical student) may use to narrow this 
broad differential diagnosis and to focus subsequent investigations.  
This case report will allow the student to develop an approach to 
hypotonia in the pediatric population. 
C ASE 
MS is a 2 year old boy who initially presented to his family physician 
at approximately 18 months when his parents noticed he was walking 
with his IHHWWXUQHGRXWDQGWKDWKHGLVSOD\HGD³ZDGGOLQJJDLW´$W
the time, the parents mentioned that their son had difficulty keeping 
up with other children when walking, and would frequently trip when 
running.  MS was subsequently referred to a general pediatrician, 
who noted proximal muscle wasting in the lower extremities, and 
calf hypertrophy bilaterally.  MS was also described as exhibiting a 
SRVLWLYH³*RZHUVLJQ´$UHIHUUDOZDVPDGHWRDQRUWKRSHGLF
surgeon, and X-rays of the lower limbs revealed no bony 
abnormalities.  Upon consultation with neurology, the patient was 
admitted to Kingston General Hospital (KGH), and several 
diagnostic investigations were performed.  The results of these 
investigations lead to a definitive diagnosis and a referral was made 
to the Child Development Centre (CDC) in Kingston, ON for follow-
up care.  To encourage reader involvement in formulating a 
GLIIHUHQWLDOGLDJQRVLVIRUWKLVFDVH06¶VGLDJQRVLVZLOOQRWEH
revealed until the end of this article. 
MS presented with his parents in consultation at the CDC at the age 
of 2 years and 1 month.  Past medical history revealed a complicated 
pregnancy, with his mother having a serious kidney infection 
requiring hospitalization at 36 weeks.  At birth, there was meconium 
staining of the amniotic fluid, and MS required suctioning and in-
hospital observation for 4-5 days.  He initially had trouble feeding 
(would gag for the first few days), but subsequently, his mom 
reported no history of gagging, choking, or trouble swallowing.  
Functionally, MS is currently able to eat with a fork and spoon, 
although his mother has noticed a tremor in his hand at times. He is 
progressing well with regards to language development, with a large 
vocabulary, and saying several two-to-three word sentences.  
Adaptively, he is able to feed himself, and is showing interest in 
being toilet-trained. 
Physical examination revealed a pleasant, engaging young boy who 
was very cooperative with most aspects of the exam.  He tended to 
SUHIHUHQWLDOO\VLWLQD³:-posture´IRUHQKDQFHGVWDELOLW\+LVJDLWLV
waddling and shows a wide-based stance.  He likes to climb, 
although he has difficulty, and will often pull on the edge of his 
shorts to lift his legs up and over obstacles.  MS demonstrates a 
SRVLWLYH³*RZHUVLJQ´ZKen getting up from the ground.  His tone is 
decreased and there is significant hypermobility of all joints.  Deep 
tendon reflexes (DTRs) are absent in the lower limbs bilaterally.  
Proximal muscle weakness is present both in the upper limbs 
(difficulty throwing a ball over his head), and the lower limbs (will 
tug on his shorts when performing a seated leg raise to kick at a ball).  
MS has functional fine motor skills that allow him to participate in a 
variety of activities.  He uses a mature pincer grasp for picking up 
small objects, and uses an age-appropriate grasp when holding a 
marker.  MS does have a noticeable tremor when completing 
activities requiring fine precision. 
DISC USSI O N 
This section of the article will aid the student in developing and 
narrowing the differential diagnosis for the presented case. 
Distinguishing upper motor neuron disorders from lower motor 
neuron disorders 
The upper motor neurons (UMN) originate in the motor cortex of the 
brain and carry motor information to the spinal cord.  Pediatric 
disorders of the UMN (characterized by hypertonia, increased DTRs, 
presence of the Babinski reflex, and an absence of muscle atrophy) 
include certain types of cerebral palsy, and chromosomal 
abnormalities (Table 1).  
The lower motor neuron (LMN) carries motor information from the 
brainstem or spinal cord out to the skeletal muscles.  LMN disorders 
are characterized by hypotonia, muscle weakness and possible 
atrophy, and reduced or absent DTRs (Table 1). 
Examining MS revealed a boy with hypotonia, muscle weakness, and 
absent DTRs, consistent with the presentation of a LMN disorder.  
Once the disorder has been identified to affect the LMN, the 
physician must further narrow the differential diagnosis by 
determining the portion of the LMN that is affected. 
Distinguishing between different LMN disorders 
The LMN is composed of the anterior horn cell of the spinal cord, 
the peripheral nerve, the neuromuscular junction, and the skeletal   
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muscle.  An LMN disorder may affect any or all of the above 
components.  Again, clinical examination will often identify the 
affected area. 
Recall that MS presented with proximal muscle weakness, absent 
DTRs, and intact sensation.  Consulting Table 2 indicates that this 
pattern is consistent with either an anterior horn cell disease, or 
possibly with a muscular disease. 
Diagnosis 
Investigations at KGH revealed a normal creatine kinase (CK) level, 
UXOLQJRXWWKHSRVVLELOLW\RI'XFKHQQH¶VPXVFXODUG\VWURSK\
(DMD).1  Subsequent EMG studies revealed normal functioning of 
the lower limb motor units, suggesting a neurogenic cause of the 
hypotonia and weakness.  Genetic testing was done and was positive 
for spinal muscle atrophy (SMA). 
SMA is an inherited degenerative neuromuscular disorder with a 
birth incidence of approximately 1 in 10,000.2  It affects the anterior 
horn cells of the spinal cord and can be clinically separated into four 
classes based on age at onset and developmental milestones achieved 
(Table 3).  Based on his presentation, it is likely that MS has Type 
IIIa SMA, although further monitoring is required to confirm this.  
There is no known effective treatment for SMA.  Patients receive 
supportive care to manage symptoms and prevent complications such 
as scoliosis and joint contractures.3,4  The prognosis varies 
considerably depending on SMA type and age at onset.5,6  MS will be 
followed every six months by the neuromuscular team at the CDC. 
C O N C L USI O N 
This case illustrates the importance of a thorough history and 
physical exam in the diagnosis of neuromuscular disorders in the 
hypotonic infant or child.  Through careful deduction, the prudent 
physician or student can arrive at a narrow differential diagnosis, 
eliminating the need for unnecessary diagnostic testing, which is of 
benefit to both young patients and their families. 
 
Table 1: Clinical Distinction between Upper Motor Neuron and 
Lower Motor Neuron Lesions
Clinical Sign 
Upper Motor 
Neuron 
(Corticospinal 
T ract) 
Lower Motor 
Neuron 
(Neuromuscular) 
Tone Increased (spastic) Decreased 
Reflexes Increased Decreased 
Babinski reflex Present Absent 
Atrophy Absent Possible 
Fasciculations Absent Possible 
From Lewis DW. Neurology. In Marcdante KJ, Kliegman RM, 
Jenson HB, Behrman RE (eds). Nelson Essentials of Pediatrics, 6th 
ed. Philadelphia, Saunders, 2011. 
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Table 2: Peripheral nervous system disorders 
 
  
Note: disease examples altered from original source to apply to pediatric population. 
Adapted from Bickley LS, Szilagyi PG: BaWHV¶*XLGHWR3K\VLFDO([DPLQDWLRQDQG+LVWRU\7DNLQJ, 10th ed. Philadelphia, 
Lippincott Williams & Wilkins, 2009.  
  
Table 3: Classification on infantile SMA 
  
From Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K: The predictive value of achieved motor 
milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 45:174-181, 2001. 
  
  
 Typical F indings  
Location of Lesion Motor Sensory Deep 
Tendon 
Reflexes 
([DPSOHVRI&DXVH 
Anterior Horn Cell Weakness and atrophy in a 
segmental or focal pattern; 
fasciculations 
 
Sensation intact Ļ Spinal muscular 
atrophy, polio 
Spinal Roots and 
Nerves 
Weakness and atrophy in a root-
innervated pattern; sometimes 
with fasciculations 
 
Corresponding 
dermatomal sensory 
deficits 
Ļ Transverse myelitis, 
herniated cervical or 
lumbar disc 
Peripheral Nerve²
Mononeuropathy 
Weakness and atrophy in a 
peripheral nerve distribution; 
sometimes with fasciculations 
 
Sensory loss in the 
pattern of that nerve 
Ļ Trauma 
Peripheral Nerve²
Polyneu-ropathy 
Weakness and atrophy more 
distal than proximal; sometimes 
with fasciculations 
Sensory deficits, 
commonly in stocking-
glove distribution 
Ļ Hereditary: Charcot-
Marie-Tooth disease 
Acquired: Guillain-
Barré syndrome 
Neuromuscular 
Junction 
Fatigability more than weakness Sensation intact Normal Infantile botulism, 
myasthenia gravis 
M uscle Weakness usually more 
proximal than distal; 
fasciculations rare 
Sensation intact 1RUPDORUĻ Muscular dystrophy 
SM A type Definition Prognosis 
I (Werdnig-Hoffmann) Onset < 6 months, never sat Death usually within the first years of 
life, chronic courses in about 10 % 
II (intermediate) 18 months, sits and stands with support, 
unaided walking not achieved 
Survival mostly into adulthood. 
III (Kugelberg-Welander) IIIa < 3 years, walks with early 
difficulties 
IIIb 3 ± 30 years, normal motor 
development 
Lifespan generally not reduced, variable 
ambulatory period 
UWOMJ | 80:S1 | Summer 2011 
8  
  
Approach to treatment decision making in an 
aggressive case of pediatric multiple sclerosis 
Lauren Sham (Meds 2014) 
Faculty Advisor: Dr. Brenda Banwell MD, FRCPC (Department of Pediatric Neurology, Hospital for Sick Children) 
 
 
C ASE 
A 13 year old previously well female presented in April 2011 with 
nausea, vertigo, mild gait ataxia, diplopia and fatigue. Her initial 
MRI (Figure 1) showed more than 20 hyperintense lesions on T2 
FLAIR that were >3 mm in size throughout the supratenetorial white 
matter, with multiple lesions in periventricular and corpus callosal 
areas. Contrast enhancing lesions were found in the right frontal lobe 
subcortical white matter, projecting from the corpus callosum, in the 
optic chiasm and superior cerebellar peduncle. Multiple T1 
hypointense black holes were also found. MRI features met 
McDonald 2010 criteria for multiple sclerosis (MS). Spinal fluid was 
positive for oligoclonal bands. She was treated with a 5 day course of 
IV solumedrol then prednisone at 50 mg/d at 10 day taper. The 
family was counseled for high risk of recurrent symptoms and 
diagnosis of MS. At the end of her course of IV steroids she had a 
near full neurological recovery with some mild residual sensory 
deficits. 
In May 2011, she began to experience left sided numbness below her 
QHFNDQGGRZQKHUOHJDQGH[KLELWHGDSRVLWLYH/¶+HUPLWWH¶VVLJQD
classic finding in MS: an electrical sensation running down the back, 
often elicited by bending the head forward). These new neurological 
symptoms localizing to the spinal cord were distinct from her initial 
presentation, which was more than 30 days previous to this attack. 
This allowed further confirmation of MS diagnosis using Poser 
clinical criteria. Steroid treatment was not initiated as the patient did 
not find these sensory symptoms bothersome. The MRI at this point 
showed some lesions decreased in size, and one new gadolinium 
enhancing lesion indicative of active inflammation. Follow up MRIs 
in July and August 2011 showed multiple new hyperintense lesions 
in the brain and spinal cord including the brainstem, some of which 
were gadolinium enhancing, and some older lesions increased in size.  
 
D O ES SH E H A V E MS? 
There have been several iterations of the diagnostic criteria for MS. 
This patient meets Poser Criteria for MS:1 two attacks and clinical 
evidence of two separate lesions involving different parts of the CNS 
separated by a period of at least one month, and each lasting a 
minimum of 24 hours. She also meets McDonald 2005 Criteria:2 
demonstrates two or more attacks and objective clinical evidence of 
two or more lesions (shows dissemination in space: two or more 
MRI-detected lesions consistent with MS, dissemination in time: two 
separate clinical attacks). Her initial MRI also met the 2005 criteria 
for lesion dissemination in space (3 of: (i) >9 T2 lesions, >3 
periventricular lesions, >1 juxtacortical lesion or (iv) >1 
infratentorial lesion). As well, her baseline MRI also met the newer  
 
 
 
F igure 1: Axial and sagital T2 FLAIR images showing 
periventricular, corpus callosal, and juxtacortical white matter 
lesions. 
 
UWOMJ | 80:S1 | Summer 2011 
CASE  REPORT  
 9  
 
McDonald 2010 Criteria:3 dissemination in space (>1 T2 lesion in at 
least 2 of 4 areas of CNS (periventricular, juxtacortical, 
infratentorial, spinal cord)) and dissemination in time (simultaneous 
presence of asymptomatic gadolinium-enhancing and nonenhancing 
lesions). CSF oligoclonal bands were present ± a finding noted in 
92% of pediatric MS patients.4 Investigations excluded other 
conditions. Thus, by all criteria, she has a diagnosis of MS. Pediatric 
MS represents up to 10% of all cases and is characterized by a 
relapsing-remitting course (RRMS). 
 
SH O U L D T R E A T M E N T B E INI T I A T E D? 
This decision can be made based on predictors of poor outcome in 
MS, as well as the natural history of the untreated disease. Based on 
data from RRMS in adults (as limited studies have been done in 
children), it has been found that early disease outcomes such as a) 
incomplete recovery from first attack and b) shorter time to second 
attack are strong predictors of poor prognosis and future disability 
(reviewed in 5), both of which this patient exhibits. The natural 
course of RRMS, if untreated, is as follows: in 10 years, 30-50% of 
patients require walking aids, and in 30 years, up to 80% require 
walking aids, and up to 30% are restricted to their bed with effective 
use of only their arms.6 Due to the certainty of her diagnosis, and 
likelihood of future disability, this patient would be counseled to 
consider treatment.  
 
C H O I C ES F O R L O N G T E R M T R E A T M E N T 
Currently there is no cure for MS. Long-term treatment encompasses 
first and second-line therapies (reviewed in 7, 8). 
 
F irst line therapy: Immunomodulation 
First line therapy for MS includes iQWHUIHURQȕ5HELI$YRQH[
Betaseron) and glatiramer acetate (Copaxone). The clinical benefit of 
LQWHUIHURQȕLVWKRXJKWWREHPHGLDWHGWKURXJKVHYHUDOPHFKDQLVPV
inhibition of proinflammatory cytokines, induction of anti-
inflammatory mediators, reduction of lymphocyte migration across 
the blood brain barrier, and inhibition of T-cell activation, among 
others. In Phase III pivotal trials in adult MS, interferon treatment 
demonstrated a 30% reduction in relapse rate compared with placebo 
for periods of 2-3 years.9 Formal trials have yet to include patients 
under 18 years old, but retrospective reviews show benefit and 
suggest safety and tolerability (reviewed in 7, 8). 
Glatiramer acetate is an acetate salt mixture of synthetic polypeptides 
designed to mimic human myelin basic protein (MBP). It is 
postulated to induce regulatory and/or suppressor T cells, shift T 
helper response from TH1 to TH2, and shift antigen presenting cell 
function to type II. It was found to reduce number of relapses by 
29% in adults with RRMS over 2 years.10 Studies in children are 
limited but it seems to be effective (reviewed in 8). 
First-line treatment failure can occur due to inadequate effectiveness 
(failure to reduce relapse rate), intolerable adverse effects or 
presence of unacceptable level of breakthrough disease (severity or 
frequency of attacks).8 It is difficult to define treatment failure and 
consensus criteria for children have not been established. However, 
one paper showed that 1/4 of children experience breakthrough 
disease and switched to second-line therapy an average of 1.5 years 
after starting first-line therapy.11 
 
Second line therapy 
Second line MS therapy includes cyclophosphamide and 
natalizumab. Cyclophosphamide acts to induce a general state of 
immunosuppression. Its mechanism is presumably through 
lymphocytotoxicity and decreasing lymphocyte subsets (reviewed in 
8). It is used in adult patients with severe active MS, and a 
retrospective study in pediatric patients with severe MS revealed a 
reduction in the mean annualized relapse rate, although 75% of 
patients acquired new lesions on MRI over 12-24 months of 
treatment.12 The risk of infertility, infection and long-term 
malignancy increases with total dose and strategies for fertility 
preservation should be considered (reviewed in 8). It is an option for 
aggressive MS refractory to first-line therapies. 
Natalizumab (Tysabri) inhibits VLA4 through binding to a subunit of 
ĮȕLQWHJULQLQKLELWLQJO\PSKRF\WHPLJUDWLRQDFURVVEORRGEUDLQ
barrier and also resulting in T-cell apoptosis. In adult MS trials, it has 
been shown to decrease relapse rates by 68% and reduce the 
formation of new enhancing lesions by >90% relative to placebo.13 
Open label case series in adolescents described a marked relapse-rate 
reduction and favorable safety profile (reviewed in 8). However, it 
has been associated with increased risk of opportunistic infection. Of 
particular concern, Tysabri has been associated with a 1/1000 
incidence of active infection with JC virus, leading to progressive 
multifocal leukoencephalopathy (PML), an infection almost 
exclusively associated with immunosuppressed patients including 
AIDS. Careful monitoring strategies including prior determination of 
JC virus serology are now in place and protocols for treatment of 
PML are being optimized (reviewed in 14). Nonetheless, PML is a 
major deterrent for widespread use of Tysabri. 
 
T W O M O D E LS O F C A R E 
The nature of MS as a chronic disease and its onset in childhood lend 
careful consideration to the intensity of initial therapy. Two potential 
models of care (as discussed in 8FDQEHFRQVLGHUHGµ6WDUWORZ
DQGHVFDODWHLIQHFHVVDU\¶DQGµ6WDUWVWURQJDQGPDLQWDLQ¶
Approach #1 is currently the standard of practice for most pediatric 
MS patients. It emphasizes greater safety with reduced potency and 
may be valuable to consider in multiple sclerosis, a disease with 
lifelong exposure to medication. Approach #2 involves powerful 
immunosuppression followed by maintenance of remission by less 
potent medications, which is similar to care of pediatric patients with 
severe rheumatological disease. It is considered for newer therapies 
and more aggressive disease, as it provides greater early disease 
suppression, which is important to consider in the context of limiting 
inflammation-mediated brain injury in the context of a developing 
pediatric CNS. However, it carries greater risk of toxicity, significant 
risk of opportunistic infection (e.g. PML in the case of Tysabri) and 
consideration of potentially life-altering decisions (e.g. fertility 
implications in the case of cyclophosphamide), which is especially 
pertinent in the care of pediatric patients. In this case of our patient: 
should the treatment decision reflect the current standard of care for 
pediatric MS patients or does her highly aggressive disease indicate 
that second line therapy should be pursued? 
 
EPI L O G U E 
The family decided to pursue cyclophosphamide as their choice of 
treatment. Though the role of the physician is to guide patients and 
their families towards appropriate treatment, it is pertinent to keep in 
mind that the family has the final decision. 
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Nodular regenerative hyperplasia of the liver 
presenting with ascites in a woman with 
limited systemic sclerosis 
Arielle Mendel (Meds 2013) 
Faculty Reviewer: Dr. Lori Albert MD, FRCPC (Division of Rheumatology, Toronto Western Hospital, University 
of Toronto) 
  C ASE  
A 57-year old Caucasian female was being followed for a 30-year 
history of limited systemic sclerosis.  Her disease first presented with 
5D\QDXG¶VSKHQRPHQRQLQDQGVKHVXEVHTXHQWO\GHYHORSHG
digital calcinosis, dysphagia and esophageal reflux, sclerodactyly, 
and widespread telangiectasia.   
In 2003, she developed progressive dyspnea on exertion 
accompanied by chest tightness and a single episode of syncope.  
Physical examination was significant for a split S2 with a loud 
pulmonic component.  Pulmonary function testing showed a 
decreased diffusion capacity.  RSVP was found to be elevated on 
2D-Echocardiogram.  These findings supported a diagnosis of 
pulmonary arterial hypertension (PAH) secondary to scleroderma.  
She received continuous IV prostacyclin infusion in combination 
with an oral prostacyclin analogue.  Sildenafil was added in 2007, 
due to worsening exercise tolerance.  She underwent evaluation for 
lung transplantation, but a decision was reached to defer the 
procedure unless her status worsened further.  
In 2007, the patient began to experience intermittent episodes of dull 
and diffuse RUQ pain.  Her abdomen was noted to be protuberant on 
several occasions.  However, repeated laboratory tests and imaging 
of abdomen and liver remained normal.  An upper GI endoscopy was 
performed in 2008 and showed no significant abnormalities.  
In June of 2011 she presented to the ER with increasing RUQ pain, 
abdominal fullness, and weight gain of 10 lbs despite decreasing 
appetite over the last 2-3 months.  There was no icterus or pedal 
edema.  AST and ALP were mildly elevated (45 IU/L and 161 IU/L 
respectively), with normal albumin and INR.  Abdominal ultrasound 
showed ascites, splenomegaly and bilateral pleural effusions, and she 
was admitted to hospital for further evaluation.  Paracentesis 
revealed a serum-to-ascites albumin gradient of 11 with no evidence 
of infection.  Hepatic venous pressure gradient was at the upper limit 
of normal (5 mmHg).  Gastroscopy showed marked portal 
hypertensive gastropathy with no significant varices.  Cardiac RVSP 
was measured at 96 mmHg (N<40 mmHg) on 2D-echocardiogram, 
which had remained stable at this level for the past few years.  
A transjugular liver needle biopsy was then performed.  This 
revealed loss of small portal veins and nodularity of the hepatic 
parenchyma with minimal fibrosis, no fibrous septa and no evidence 
of cirrhosis or other disease.  Of note, bile ducts were present in 
normal numbers and appeared normal, with no observed cholestasis.  
These histological changes were diagnostic for Nodular Regenerative 
Hyperplasia (NRH) of the liver.  
The treating physicians felt that this SDWLHQW¶VSUHVHQWDWLRQRI584
pain with ascites was the result of non-cirrhotic portal hypertension 
secondary to NRH, which was further exacerbated by severe PAH.  
The patient was treated with gentle diuresis and supportive 
management, and over the course of her admission her ascites 
diminished moderately and pleural effusions resolved.  It was 
recognized that aggressive dieresis, therapeutic paracentesis or a 
transjugular intrahepatic portosystemic shunt (TIPS) procedure were 
all contraindicated given her fragile cardio-pulmonary status 
secondary to PAH.  She was discharged after two weeks on 
spironolactone, a no added salt diet, and continued close monitoring 
of fluid balance.  Unfortunately, this complication of her disease will 
limit her suitability for future lung transplantation. 
 
DISC USSI O N 
Systemic sclerosis (SSc) or scleroderma is a rare disease 
characterized by progressive fibrosis of cutaneous, vascular and/or 
visceral connective tissue.1  The pathogenesis is linked to sustained 
immune-mediated activation of fibroblasts and endothelial cells.2  
7KHµOLPLWHG¶RUµGLIIXVH¶VXEW\SHVRI66FGLIIHUZLWKUHVSHFWWRWKH
extent of skin fibrosis, organ involvement, antibody production, and 
survival.1,3  Features of limited SSc (l-SSc) include the CREST 
syndrome (calcinosis cutis5D\QDXG¶VSKHQRPHQRQHVRSKDJHDO
dysmotility, sclerodactyly, telangiectasia) and anti-centromere 
antibodies.4  Patients with either subtype require continuous 
monitoring for specific organ complications, and supportive 
treatment targeted towards affected tissues. 
Nodular regenerative hyperplasia (NRH) is a pathological description 
for abnormal regenerative nodules within the hepatic parenchyma in 
the absence of fibrosis.5  NRH is rare diagnosis, known to develop in 
the context of autoimmune, hematologic and malignant disorders as 
well as certain drug exposures.5  In a case series of 42 patients with 
NRH, one quarter had an underlying rheumatologic disorder6, and a 
recent review found 7 reports of NRH associated with SSc or CREST 
syndrome.5 
The regenerative nodules in NRH are thought to be a reactive process 
of hepatocytes secondary to disrupted vascular flow.5  Clinically, 
NRH belongs to a heterogeneous group of disorders causing non-
cirrhotic portal hypertension, characterized by elevated portal 
pressures, ascites, or varices in the absence of cirrhosis or significant 
liver dysfunction.7,8  The pathogenesis of non-cirrhotic portal 
hypertension likely involves pre-sinusoidal and portal vessel injury, 
fibrosis, and thrombosis.5,7  The chronic inflammation, auto-
antibodies, and pro-thrombotic state present in rheumatic diseases 
may precipitate this process.6,9  In SSc, the abnormal fibroblast 
activity responsible for cutaneous thickening may also be present in  
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the portal tracts.10  
Although non-specific liver abnormalities are common in SSc11, 
intrinsic liver disease is seen infrequently.12 Primary Biliary 
Cirrhosis (PBC), involving progressive obliteration and fibrosis of 
intrahepatic bile ducts, is the liver disease most commonly associated 
with l-SSc.9,11,13  Conversely, NRH is a very rare complication12,14, 
and only case reports exist in the literature.5  Interestingly, NRH has 
been reported as an overlap syndrome with PBC in patients with 
CREST.15,16  In this patient, a minimally elevated ALP in the 
presence of normal bile ducts in the biopsy specimen makes a 
diagnosis of overlapping PBC unlikely.15  
NRH should be considered in the context of preserved liver function, 
minimally elevated liver enzymes, and no evidence of cirrhosis.5  
The diagnostic gold standard for NRH is liver biopsy14; imaging and 
other non-invasive tests are less helpful diagnostically.5,17  
Management consists of treating the underlying condition(s) and 
preventing or treating portal hypertension, as these are the main 
prognostic factors in this condition.5,6  
Portal hypertension will eventually develop in 50% of patients with 
NRH, but it is uncommon for manifestations such as ascites to be 
present at the time of diagnosis.6,15 One of the factors that likely 
FRQWULEXWHGWRWKLVSDWLHQW¶VGUDPDWLFSUHVHQWDWLRQZDVKHUORQJ-
standing pulmonary arterial hypertension (PAH), which is estimated 
to affect 10-25% of SSc patients.18  Prostacyclin analogues, 
endothelin-receptor antagonists and PDE-5 inhibitors have been 
shown to improve function and delay progression in patients with 
PAH-SSc19,20, but it remains the leading cause of mortality in 
patients with l-SSc.18   Interestingly, there have been numerous 
reports of NRH co-existing with PAH in patients with SSc and other 
diseases, suggesting that a common vascular pathogenesis may 
underlie these conditions.5,15,21,22  Alternatively, PAH may be 
responsible for producing the circulatory disturbance that initiates the 
development of NRH.22 
This is an example of a rare condition, Nodular Regenerative 
Hyperplasia of the Liver, presenting in a relatively rare disease, 
scleroderma.  The initially subtle signs and lack of laboratory 
abnormalities further confounded efforts to identify the underlying 
problem.  Our patient had a prolonged stay in hospital, and the ability 
to make the diagnosis and provide appropriate care required the 
collaboration with, and expertise of hepatologists, gastroenterologists 
and respirologists.  This case highlights the need for 
multidisciplinary management of patients with complex rheumatic 
disorder, particularly in the setting of diagnostic and therapeutic 
dilemmas.  Further research is warranted to investigate the 
relationship between pulmonary hypertension and the vascular 
pathogenesis of NRH.  
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Gastric Schwannoma: a rare Schwann cell 
tumour of the GI tract 
Mark Xu (Meds 2014) 
Faculty Reviewer: Dr. Steven Latosinsky MD, MSc, FRCSC (Department of General Surgery, Victoria Hospital, 
LHSC) 
 
Schwannomas are benign, slow-growing, encapsulated nerve-sheath 
tumors arising from Schwann cells, which are responsible for the 
myelin sheath in the peripheral nervous system.1 Schwannomas are 
most commonly found in the cranial vault, involving the myelin-
forming cells of the 8th cranial nerve, in a condition called vestibular 
neuroma.2 In rare cases, they can also occur in the GI tract, usually in 
the stomach.3 GI schwannomas are often non-encapsulated, but well 
demarcated.4 
Gastric schwannomas account for only 0.2% of all gastric tumors and 
4% of all benign gastric neoplasms.5 The peak incidence is in the 4th 
and 5th decade of life, usually involving females.5,6 They can also 
occur in children, and can be malignant in rare cases.7 The majority 
of patients have remained asymptomatic for extended periods of 
time, with most cases discovered incidentally on imaging or 
laparotomy.5,8 Symptomatic patients most often present with 
ulcerations and upper GI bleeding, and a palpable mass may be 
present if the tumor grows exophytically.5 Malignant transformations 
are exceedingly rare, but have been reported.9 
 
C ASE 
The patient is a 34-year-old female who presented to the ER with 
RLQ pain and lower back pain persisting for the past 10 days. Her 
vital signs were stable with a normal white cell count.  
CT-scan of her abdomen showed a normal appearing appendix. Fluid 
was seen in the pelvis, possibly secondary to a ruptured ovarian cyst. 
There was an incidental finding of a mass that appeared to be arising 
from the stomach. The mass appeared intramural and measured 5.1 
cm x 4.4 cm. An ultrasound was done to look at lesions in the liver 
which were felt to be hemangiomas. 
7KHSDWLHQW¶VSDLQZDVVRPHZKDWFRQWUROOHGZLWKPRUSKLQHDOWKRXJK
it was still present. No cause of pain was determined. She was 
discharged from the emergency department with Percocet and 
scheduled to return for an esophagogastroduodenoscopy (EGD) 
approximately 4 weeks later. 
8SRQUHWXUQIRUWKH(*'WKHSDWLHQW¶VSDLQZDVPXFKLPSURYHGDQG
she discontinued all her pain medications. The EGD showed a 
submucosal mass 5 cm below the gastroesophageal junction. The 
patient was referred to GI to for endoscopic ultrasound (EUS). 
When seen by GI one month later, the patient revealed a prior history 
of anxiety disorder and was being treated with Paxil. She also had 
constitutional symptoms of anorexia and reported a 45-pound weight 
loss. An upper endoscopy was performed and the gastric mass was 
visualized along the lesser curvature of the stomach. The mass felt 
firm when probed.  
 
F igure 1. Abdominal CT scan showing LUQ mass. 
 
On endoscopic ultrasound, the mass appeared hypoechoic but had 
evidence of hyperechogenicity foci. It measured 5.2 cm x 3.3 cm in 
its largest dimensions and was well demarcated, originating from the 
muscularis propia of the stomach. There was evidence of a 
perigastric lymph node as well as two celiac lymph nodes. A fine 
needle aspiration (FNA) for cytology as well as a core biopsy for 
histopathology was performed on the primary mass and one of the 
nodes. The mass was not endoscopically resectable. 
Microscopic evaluation of lesion cells revealed a palisaded growth 
configuration, with elongated spindled nuclei and pointed ends. No 
mitosis or necrosis was seen. Immunochemistry was positive for S-
100; negative for CD117, CD34, desmin, muscle specific actin and 
caldesmon. These findings were consistent with a diagnosis of 
schwannoma. 
An ultrasound was done approximately 6 months later to reassess the 
mass, which appeared unchanged. She is currently being followed 
with annual CT-scans; no surgery is planned. 
 
D ISC USSI O N 
This is an interesting case of a gastric mass found incidentally for the 
presentation of right lower quadrant pain.  
Briefly, the presenting pain was relatively severe and never 
explained. Appendicitis is the most likely cause of acute RLQ pain,10 
EXWRXUSDWLHQWV¶DSSHQGL[DSSHDUHGQRUPDORQ&7-scan. There was 
also suspicion of a ruptured ovarian cyst based on fluid seen in the 
pelvis on ultrasound. However, the ovaries were normal and this 
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GLDJQRVLV ZDV VRPHZKDW LQFRQVLVWHQW ZLWK WKH SDWLHQW¶V -day 
history of pain: fluid from an uncomplicated ruptured ovarian cyst is 
normally reabsorbed in 24 hours, with the pain resolving in a few 
days.11 The pain did resolve, and further investigations focused on 
the incidental gastric mass. 
The differential diagnosis of a submucosal gastric mass is broad and 
includes gastrointestinal stromal tumor (GIST), leiomyoma, 
leimyosarcoma, and schwannoma, among others.12 Upper endoscopy 
is useful in examining epithelial tumors; however, it is inadequate for 
examining tumors below the mucosa.13 In contrast, EUS is effective 
in visualizing submucosal tissue adjacent to the gastric wall and can 
be used to precisely guide needle biopsies.13  
It is important to differentiate between gastric schwannomas and 
other mesenchymal tumors, particularly the main differential of 
GIST, which has a higher chance of being malignant. The diagnosis 
of a GIST would mandate surgical resection if possible. Imatinab is 
used both as an adjuvant therapy when the GIST is completely 
excised and palliatively for unresectable or metastatic  disease.1,14,15 
It was found that virtually all cases of GIST would exhibit malignant 
behavior if followed, and metastatic cases can be effectively treated 
with imatinib mesylate, which improves survival from <50% to 
>90% at 1 year.14,15 In comparison, schwannomas remain benign in 
nearly all cases, and are rarely symptomatic.5 As the tumor enlarges, 
it displaces the nerve to the periphery, preserving its function.16 
Symptoms can result from the enlarging submucosal tumor 
restricting circulation to the mucosa, leaving it ischemic and prone to 
ulceration, bleeding, and damage by gastric acidity.17 
Imaging modalities such as CT, ultrasound, and MRI can provide 
limited but useful information. Schwannomas often appear uniform 
on CT, which can distinguish it from leiomyomas and 
leiomyosarcomas; ultrasound with a sufficient resolution can 
GHWHUPLQHWKHWXPRU¶VOD\HUVRIRULJLQDQG05,FDQPDSWKHSUHFLVH
location of the tumor and the displacement of its surrounding 
organs.18,19,20 These findings may also be helpful in explaining the 
cause of symptoms as well as determining the best approach to 
treatment, particularly in surgical cases.  
Due to the similar spindle-shaped appearance of schwannomas and 
other gastric mesenchymal tumors, it can be difficult to distinguish 
between them using light microscopy.21 Grossly, they resemble 
leiomyomas and other stromal tumors: solitary, firm, smooth, white-
ish in color, and well circumscribed.5 Advances in 
immunohistochemistry allowed for a more precise differentiation: in 
one study, 24 out of 306 gastric spindle-cell tumors were diagnosed 
as schwannomas using immunohistochemistry, but only 9 were 
diagnosed as schwannomas using hematoxylin-eosin.22 
Immunohistochemical diagnosis of schwannoma is based on 
positivity for the S-100 protein, and negativity for CD117, CD34, 
desmin, and muscle specific actin.23 CD117 and CD34 are positive in 
GIST, and muscle specific proteins such as actin, desmin, and 
caldesmon are positive in smooth muscle tumors such as leiomyoma 
and leiomyosarcoma; all of which are negative in schwannomas.23 
Our patient¶s results are congruent with this guideline and a 
definitive diagnosis of schwannoma can be made. 
Surgical treatment for gastric schwannomas would involve complete 
resection of the tumor.24 For our patient, this would mean a 
gastrectomy: the complete or partial excision of the stomach. The 
post-operative prognosis is excellent5,1 and most patients return to 
their pre-operative quality of life;25,26 however, it is debatable 
whether or not surgery should be deemed necessary for benign, 
asymptomatic schwannoma patients. In our opinion, surgery should 
be reserved for either malignancy or for symptomatic cases, 
especially for difficult operations such as in our patient. Most of the 
literature on surgical outcome appears to be based on cases were 
diagnosed as schwannomas post-operatively; therefore, the benefits 
of surgery for known asymptomatic cases are unclear.  
Taking into account the available information, we felt that it was best 
to follow our patient with annual CT-scans, and to defer any surgical 
intervention until her symptoms become unmanageable; or until the 
improbable event that her tumor becomes malignant. 
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Diabetic Foot Syndrome in a Middle Aged Male 
with Complicated Type II Diabetes 
Jeffrey M. Landreville (Meds 2014) 
Faculty Reviewer: Dr. Heather Percival MD, CCFP (Department of Family Medicine, Seaforth Community 
Hospital) 
 Diabetes mellitus (Diabetes) represents a group of metabolic 
disorders characterized by elevated plasma glucose levels and 
abnormal insulin activity within the body.  Diabetes can be further 
classified into Type 1 (T1DM) and Type 2 (T2DM).  T1DM is 
caused by an autoimmune failure of the beta cells in the pancreas 
leading to the complete absence of insulin in the body.  In T2DM, 
hyperglycemia stems from a combination of insulin resistance, 
insulin deficiency and abnormal glucagon synthesis.1  
The number of individuals with diabetes has been increasing at an 
alarming rate.  In 2000, the worldwide prevalence of diabetes was 
estimated to be over 150 million.  It is projected that in 2025 this 
number will reach 380 million.2  Within Canada, it is projected that 
2.4 million Canadians will have diabetes by the year 2016.3  
Diabetes is a serious condition that can lead to a wide variety of life 
threatening macrovascular (coronary artery disease, peripheral 
arterial disease, stroke) and microvascular (nephropathy, neuropathy, 
retinopathy) complications.4  The constellation of lower limb 
complications associated with diabetes such as ulcers and infections 
can be referred to as a diabetic foot syndrome (DFS).5  The following 
case will highlight the management of DFS with particular attention 
to diabetic foot infection.   
 
C ASE  
Mr. D is a 41-year old resident of Southwestern Ontario who 
presented to a rural emergency department (ER) following a 
penetrating injury to the plantar surface of his left foot.  The patient 
reported that he inadvertently stepped on a nail several days prior but 
failed to notice his foot had been injured.  Mr. D denied any pain and 
disclosed that he has been diagnosed with T2DM for many years.  In 
addition to the wound on the left foot, physical examination revealed 
the patient to be obese (BMI 44) with retinopathy, neuropathy, and a 
diabetic ulcer on the right foot.  His current medications are: 
Metformin 1000 mg bid; Atacand 4 mg od; Losec 20 mg od; Lasix 
40 mg od; Gabapentin 300 mg tid; Ditropan 5 mg bid; Vitamin D 
1000iu od; Lantus insulin 51u hs; and Humalog 30u tid (adjusted +/- 
2u).  The ER physician cleaned the wound, confirmed a recent 
tetanus vaccination and prescribed Cirpofloxacin 500 mg bid with 
the explicit instructions for the patient to rest his foot. 
One week following discharge, Mr. D re-presented to the ER, 
reporting that his left foot appeared worse.  Physical examination 
revealed a grossly swollen, erythematous foot that felt warm to 
touch.  The ER physician diagnosed Mr. D with an infected diabetic 
foot and performed an incision and drainage.  A tissue specimen 
wound culture was obtained and grew mixed flora.  The patient was 
admitted to hospital for IV antibiotics (Cirpofloxacin 500 mg bid and 
Clindamycin 600 mg tid) and strict bed rest.  On admission the 
patient was afebrile with a WBC of 5.4 x109/L (normal 4-10).  
)ROORZLQJWZRGD\VRIWUHDWPHQWWKHLQIODPPDWLRQLQ0U'¶VIRRW
appeared markedly decreased and he was discharged from hospital 
on the third day.  A follow-up physical exam by his primary care 
physician revealed the left foot to be completely absent of any signs 
of infection. 
 
DISC USSI O N 
Foot infections are very common in patients with diabetes.  Together 
with foot ulceration, foot infections have been identified as a major 
cause of morbidity and mortality in the diabetic patient as well as a 
major expense to health care systems.6,7  The propensity for diabetic 
patients to develop foot infections can be attributed to three 
pathological processes: neuropathy, vascular insufficiency and 
diminished neutrophil function.8  Patients displaying symptomatic 
peripheral neuropathy lose ability to sense pain in their lower 
extremities and thus fail to notice the presence of an abrasion, blister 
or penetrating trauma.9  In addition, the vascular insufficiency and 
diminished neutrophil function impairs the immune response.10  
Together, these factors promote colonization of the wound by 
pathogenic organisms and the spread of infection from the surface to 
deeper tissue.8  
 The diagnosis of diabetic foot infection is made clinically based on 
the presence of pus or at least two cardinal manifestations of 
inflammation (erythema, warmth, swelling or induration, and pain or 
tenderness).  It is important to note that the presentation will vary 
from patient to patient.  If peripheral neuropathy is present, the 
patient may report diminished or absent pain at the site of infection.  
Furthermore, 50% of diabetic patients with a significant foot 
infection will not have systemic signs of fever or leukocytosis due to 
a blunted cellular response to the infection.11  
Aggressive management of diabetic foot infections is crucial.  Left 
untreated, these infections progress to gangrene and eventually 
require amputation of the limb.  The wound should be cleaned, 
debrided and probed to identify sinus tracts, abscesses and the 
presence of osteomyolitis.9  Tissue specimens for wound culture 
should be obtained by scraping the base of the ulcer with a scalpel 
blade and processed for a Gram stained smear and aerobic/anaerobic 
cultures.12  Initial antibiotic therapy is empiric, broad spectrum and 
based on the severity of the infection.  Severe infections require 
agents with coverage against Gram positive (including MRSA if 
necessary), Gram negative and anaerobic organisms.  The patient 
should be evaluated for response to therapy in 1-3 days.  If indicated 
by early culture results a modification to their antibiotic regimen can  
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 occur at this time.  Severe diabetic foot infections often require surgical management including incision and drainage, surgical 
debridement, revascularization and amputation.9  Following 
treatment, appropriate wound care is essential.  Removing pressure 
from the wound, minimizing leg edema and maintaining a moist 
wound environment are all important factors that promote wound 
healing.13,14,15   
Of all the diabetes related hospital admissions in North America, 
DFS accounts for 20%.16,17  A focus on the prevention of DFS in 
diabetic patients will not only improve the quality of life of those 
patients but also help reduce the burden diabetic patients place on 
health care systems.  It is recommended that diabetic patients engage 
in regular foot examinations.18  Higher risk individuals require foot 
care education regarding the avoidance of foot trauma, properly 
fitted footwear, smoking cessation strategies and optimization of 
glycemic control.19  Those who develop foot ulcers require 
management by multidisciplinary teams involving individuals 
specialized in diabetic foot care.20  
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A 19 year old with a bilateral posterior sub-
capsular cataract (PSCC) induced by 
corticosteroid cream  
Abdul Naeem (Meds 2014) 
Faculty Reviewer: Dr. Baseer Khan MD, FRCSC (Department of Opthalmology and Vision Services, University of 
Toronto, Mount Sinai Hospital, Clarity Eye Institute) 
 
 
C ASE 
We present a case of a healthy 19 year old female on a three month 
follow-up to our clinic with a bilateral posterior sub-capsular cataract 
(PSCC) induced by a corticosteroid cream she used for one month 
due to her atopic dermatitis.  All remaining medical history and 
systems review are normal.  She is currently not on any medications.  
In her right (OD) eye her uncorrected vision (sc) is CF @ 4 ft, 
corrected vision (cc) is 20/40 and IOP is 12.  In her left (OS) eye her 
uncorrected vision is 20/400, corrected vision (cc) is 20/70-2 and 
IOP is 13.  
 
DISC USSI O N 
Cataract is the leading cause of blindness in the world.1 A cataract 
(from the Latin cataracta meaning waterfall) is defined as the 
clouding of the crystalline lens of the eyes.  In normal healthy 
humans, the lens of the eye is usually clear whereas a person with 
cataracts may have a lens varying from slight to complete opacity.  
Until the fourth decade of life, the lens is able to change its shape.  
This allows the lens to focus on near and far away objects.  The lens 
focuses the light rays on the back of the eye and the light signal is 
transmitted to the brain via the optic nerve.  
In normal humans since embryonic development and onwards the 
lens of the eyes produce specialized cells that are arranged in a 
specific and complex orientation.2  These cells in the lens of the eye 
are stratified epithelia and contain large amounts of cytoplasmic 
proteins.  These proteins are called crystallins and are transparent.2  
However, the lens are unique in the sense that they "do not shed 
nonviable cells"3 and so the "lens is susceptible to degenerative 
effects of aging on cell structure"3.  And so subsequently with 
advanced aging of the lens, the lens becomes cloudy.  This 
cloudiness or cataract can then obstruct the passage of light and in 
effect cause deviation from normal vision.  
Factors that may lead to cataract formation are: advanced age, 
smoking, alcohol consumption, poor lifestyle habits (including 
malnutrition and physical inactivity), long-term exposure to 
ultraviolet light or radiation, congenital factors, surgical 
complications, corticosteroid drugs, and secondary effects of diseases 
such as diabetes, hypertension and trauma.4,5 
In the case presented, the cause of cataracts was eye exposure to a 
corticosteroid cream used for atopic dermatitis.  Corticosteroids are 
heavily used for treating localized and systemic inflammatory 
conditions in dermatology.  The administration methods are usually 
topical, oral or inhaled.  Corticosteroids affect a large spectrum of 
bodily systems and specifically may result in an early forming 
cataract and an increase in intra-ocular pressure (IOP), which is a 
risk factor for Glaucoma.  With this in mind, corticosteroids should 
be prescribed with time spent on patient education and possible 
treatment complications.  
The patient presented in this case was monitored for IOP, which was 
noted as stable and normal. However, she did develop a sub-capsular 
cataract, which is formed in the posterior portion of the lens.  This 
type of cataract is "particularly visually disabling"6 as it is formed 
"nearest to the eye's focusing or nodal point". 6  In terms of 
corticosteroid administration, "topical steroids have the most effect 
followed by oral/parenterally administered formulations".6  There is 
some research also suggesting that inhaled corticosteroids may lead 
to cataract formation as well.  
In conclusion, though cataracts can be quite disabling and can 
significantly affect the quality of life of a patient, they do not damage 
the eye.  With the technological advances in cataract surgery, 
cataract extraction can be successfully managed with an outpatient 
procedure.7,8  Patients are usually seeing a lot better within 24 hours.  
Considerations for surgery, risk factors, and options for intra-ocular 
lens, were discussed with our patient.  In this case, the patient still 
had quite a bit of manageable vision and decided to watch and wait 
for now.  A follow-up of 6 months was scheduled when her eyes will 
be reassessed and operated on if she agrees and meets the surgical 
indications.  Indications for surgery would include difficulty with 
routine daily activities of living, school or driving. 
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